View Older Stories

Feb 24, 2026 10:13AM Palvella Therapeutics (PVLA) PT Raised to $255 at H.C. Wainwright

Feb 23, 2026 06:57AM Raymond James Reiterates Strong Buy Rating on Palvella Therapeutics (PVLA)

Feb 4, 2026 04:12PM Clear Street Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Feb 2, 2026 07:30AM Palvella Therapeutics publishes systematic review on statin use in porokeratosis

Feb 2, 2026 05:20AM Palvella Therapeutics (PVLA) PT Raised to $190 at TD Cowen

Jan 9, 2026 07:30AM Palvella plans March 2026 data readout for rare skin disease drug

Jan 8, 2026 09:20AM TD Cowen on Palvella Therapeutics' (PVLA) SELVA Data Preview: 'High Conviction for Success'

Jan 7, 2026 05:49AM Mizuho Starts Palvella Therapeutics (PVLA) at Outperform, PT $205, trading $91 handle now

Jan 2, 2026 07:32AM Palvella Therapeutics (PVLA) files $300M mixed shelf

Dec 16, 2025 06:54AM Palvella Therapeutics (PVLA) PT Raised to $193 at Raymond James

Dec 16, 2025 06:09AM Palvella Therapeutics (PVLA) PT Raised to $133 at TD Cowen

Dec 16, 2025 03:50AM Palvella Therapeutics (PVLA) PT Raised to $174 at Chardan Capital Markets

Dec 15, 2025 03:03PM Palvella Therapeutics (PVLA) PT Raised to $192 at BTIG

Dec 15, 2025 02:14PM Palvella Therapeutics (PVLA) PT Raised to $190 at Truist Securities

Dec 15, 2025 01:49PM Clear Street on Palvella Therapeutics (PVLA): 'Management highlighted continued momentum across the pipeline'

Dec 15, 2025 12:44PM Palvella Therapeutics (PVLA) PT Raised to $143 at Jones Trading

Dec 15, 2025 12:29PM Palvella Therapeutics (PVLA) PT Raised to $204 at Canaccord Genuity

Dec 15, 2025 12:17PM Palvella Therapeutics (PVLA) PT Raised to $200 at H.C. Wainwright

Dec 15, 2025 10:30AM Palvella Therapeutics (PVLA) PT Raised to $200 at Oppenheimer

Dec 15, 2025 10:09AM Palvella Therapeutics (PVLA) PT Raised to $210 at Cantor Fitzgerald

Dec 15, 2025 10:06AM Palvella Therapeutics (PVLA) PT Raised to $212 at Lucid Capital Markets

Dec 15, 2025 08:55AM Raymond James Reiterates Strong Buy Rating on Palvella Therapeutics (PVLA)

Dec 11, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Dec 5, 2025 06:03AM BTIG Starts Palvella Therapeutics (PVLA) at Buy

Dec 4, 2025 04:41PM Clear Street Starts Palvella Therapeutics (PVLA) at Buy, PT $200

Dec 4, 2025 07:09AM Craig-Hallum Starts Palvella Therapeutics (PVLA) at Buy

Nov 24, 2025 04:12AM Palvella Therapeutics (PVLA) PT Raised to $145 at Stifel

Nov 19, 2025 06:36AM Raymond James Upgrades Palvella Therapeutics (PVLA) to Strong Buy

Nov 11, 2025 12:49PM Palvella Therapeutics (PVLA) PT Raised to $120 at Oppenheimer, 'We're Buyers into Key Data'

Nov 10, 2025 06:10AM Palvella Therapeutics (PVLA) PT Raised to $105 at Truist Securities

Nov 5, 2025 05:31PM Palvella Therapeutics (PVLA) PT Raised to $97 at TD Cowen

Nov 5, 2025 12:33PM Palvella Therapeutics (PVLA) PT Raised to $87 at Stifel

Nov 5, 2025 06:00AM Palvella announces new drug candidate for rare skin disease

Oct 17, 2025 08:32AM Truist Securities: 'Is Biotech Back?!'

Oct 9, 2025 06:36AM Palvella Therapeutics (PVLA) PT Raised to $90 at Canaccord Genuity

Oct 2, 2025 08:37AM Palvella Therapeutics (PVLA) PT Raised to $80 at Truist Securities

Sep 26, 2025 06:45AM Palvella Therapeutics (PVLA) PT Raised to $95 at H.C. Wainwright

Sep 25, 2025 03:12AM Palvella Therapeutics (PVLA) PT Raised to $70 at Jones Trading

Sep 24, 2025 01:17PM Palvella Therapeutics (PVLA) PT Raised to $90 at Oppenheimer

Sep 24, 2025 12:41PM Palvella Therapeutics (PVLA) PT Raised to $80 at Stifel

Sep 24, 2025 06:01AM Palvella expands QTORIN rapamycin development to angiokeratomas

Sep 19, 2025 06:50AM H.C. Wainwright Reiterates Buy Rating on Palvella Therapeutics (PVLA)

Sep 17, 2025 07:33AM Palvella announces scientific publication on rapamycin for venous malformations

Sep 9, 2025 06:04AM Oppenheimer Starts Palvella Therapeutics (PVLA) at Outperform, PT $85

Sep 3, 2025 07:31AM Palvella appoints David Osborne as chief innovation officer

Aug 19, 2025 06:18AM Palvella Therapeutics (PVLA) PT Raised to $66 at Canaccord Genuity

Aug 18, 2025 06:48AM Palvella Therapeutics (PVLA) PT Raised to $75 at H.C. Wainwright

Aug 5, 2025 04:07PM Raymond James Starts Palvella Therapeutics (PVLA) at Outperform

Jul 21, 2025 07:32AM Truist Securities Starts Palvella Therapeutics (PVLA) at Buy

Jun 9, 2025 07:30AM Palvella Therapeutics (PVLA) Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN

View Older Stories